Valeant Pharmaceuticals To Hold Conference Call On March 15, 2016

LAVAL, Quebec, March 7, 2016 /CNW/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that it plans to host a conference call and live webcast on March 15, 2016 to discuss preliminary fourth quarter 2015 financial results and update 2016 financial guidance.      

"We are looking forward to providing Valeant shareholders with an update on the company's progress," stated J. Michael Pearson, chief executive officer.  "February 29th was my first day back to work following a two month medical absence. Now that I have returned, I have been working diligently to review the business so that I can share our latest performance and outlook with shareholders."

Conference Call Details:


Tuesday, March 15, 2016


8:00 a.m. ET


Participant Event Dial-in 

(877) 295-5743 (North America)

(973) 200-3961 (International) 

Participant Passcode


Replay Dial-in

(855) 859-2056 (North America)

(404) 537-3406 (International) 

Replay Passcode

66610318  (Replay available until 03/22/2016)

About Valeant

Valeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, eye health, neurology and branded generics. More information about Valeant can be found at

Forward-looking Statements

 This press release may contain forward-looking statements, including, but not limited to, statements regarding Valeant's financial reporting and future prospects.  Forward-looking statements may generally be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," "target," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in the Company's most recent annual or quarterly report and detailed from time to time in Valeant's other filings with the Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements.  These forward-looking statements speak only as of the date hereof. Valeant undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes, unless required by law.

Contact Information:
Laurie W. Little        

Elif McDonald


Logo -


SOURCE Valeant Pharmaceuticals International, Inc.

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890